Pharma Market Size by Therapy Area
Where the next $1T of growth actually sits.
A decision-grade map of pharma market size, growth and modality mix at therapy-area level — for strategy, BD and investor teams sizing real opportunities, not headline numbers.
"Should we play in this therapy area — and at what scale?"
Global pharma is ~$1.9T today, projected to ~$4T by 2034. Oncology, immunology, metabolic disease and rare disease account for most growth — but only a few sub-segments remain unsaturated.
Sizing a pharma therapy area is the first decision that determines every downstream call — what to license, what to acquire, where to launch, what to deprioritize. Most teams still rely on a single secondary-research number for the TAM, then make billion-dollar calls against it. Decision intelligence treats the TA size as a live, model-driven number with explicit assumptions and a ±range.
Why TA-level sizing is the wrong place to stop
“Oncology is a $250B market” is technically true and operationally useless. The sub-segment that actually matters might be HER2-low metastatic breast cancer 2L+ with maybe $4–6B of addressable spend, three credible candidates and one looming patent cliff. Decisions get made at that resolution.
The four numbers every TA model needs
A defensible therapy-area model surfaces four numbers per segment: current addressable spend, 5-year forecast (base / upside / downside), net competitive whitespace after pipeline and LoE, and geo-adjusted value after reimbursement. Anything less is research, not intelligence.
From sizing to decision
Once the TA model is in place, it becomes the same engine that powers go/no-go on licensing, in-house R&D prioritization, BD target screening and country launch sequencing. The output isn’t a slide — it’s a portal where strategy, BD and finance see the same numbers update in real time.
What we’re seeing in the data.
Headline TAM ≠ addressable opportunity
A $200B therapy area can have <$5B of unsaturated whitespace once you exclude entrenched standards-of-care and pending generics.
Modality-shift is the real driver
mRNA, ADCs, cell & gene therapies are reshaping growth curves inside each TA — and changing who the credible competitors are.
Country mix matters as much as TA mix
US still drives 50%+ of pharma economics. China and emerging markets matter for volume; ex-US pricing controls cap upside.
Generics and biosimilars compress fast
Patent expiries within a TA can reset the addressable market by 30–50% in 24 months — making forward-looking sizing more important than current spend.
How to think about it.
-
01
Anchor on the therapy area definition
Lock the indication boundary before sizing — solid tumor oncology, B-cell hematology and CAR-T are different markets.
-
02
Decompose into segments and modality
Split TA into segments (line of therapy, biomarker, age) and modality (small mol, biologic, ATMP).
-
03
Forecast unit growth and pricing separately
Volume drivers (incidence, screening, access) and price drivers (mix shift, LoE, payer pressure) move in opposite directions.
-
04
Apply LoE and competitive haircuts
Layer in patent expiries, biosimilar entry and pipeline competition to get net addressable opportunity.
-
05
Express as base / upside / downside
Defensible answers come as ranges with explicit assumptions, not single-point forecasts.
What separates a good answer from a defensible one.
A $40B "global" TA can be $20B once you net out HTA-driven price erosion outside the US.
Three credible Phase 3 candidates with the same MoA usually cap any single asset’s peak share at 25–35%.
In oncology and immunology, combinations expand the TA but redistribute economics across MoA classes.
Trial-grade evidence often overstates real-world uptake by 12–24 months — model the lag.
Where the signal comes from.
Common questions.
How granular should TA sizing be?
Down to indication × line of therapy × biomarker × geography. Anything coarser hides the actual opportunity.
How often should the model refresh?
Quarterly at minimum — pipeline news, regulatory decisions and HTA outcomes can shift sizing materially.
Do you build this as a one-off or a system?
Both, but the durable answer is a TA-sizing system fed by trial, deal and price data, not a one-off slide deck.
What do investors most often get wrong?
They size on today’s pricing, not 5-year LoE-adjusted pricing. That single correction reshapes most TA-investment decisions.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist